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Background Dysregulated nitric oxide (NO) signaling contributes to the pathogenesis of hypertension. Previously, we reported gender-and strain-specific hypertension in mice deficient in the α1-subunit of the NO receptor soluble guanylate cyclase (sGCα1 -/-): male mice on an Sv129/J (S6) but not a C57BL6/J (B6) background are hypertensive.
Methods and results
Via linkage analysis, we identified a quantitative trait locus (QTL) associated with elevated blood pressure in male sGCα1 -/-S6 mice. This QTL encompasses CYP4a12a, encoding the predominant murine synthase of the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE). Renal expression of CYP4a12awas strain-, gender-, and testosterone-dependent:CYP4a12a gene expression was higher in male WT and sGCα 1 -/-S6 mice than in female S6 mice, or than in male and female, WT and sGCα 1 -/-B6 mice, higher in testosterone-treated S6 mice than in vehicle-treated S6 mice, and higher in sham-operated S6 mice than orchiectomized S6 mice. Also, 20-HETE levels were higher in renal preglomerular microvessels of male sGCα1 -/-S6 than of sGCα1 -/-B6 mice. Furthermore, the 20-HETE antagonist 20-6,15-HEDGE lowered blood pressure in male sGCα 1 -/-S6 but not WT mice. Finally, the more significant impairment of acetylcholine-induced relaxation of renal interlobar arteries in male sGCα 1 -/-S6 than sGCα 1 -/-B6 mice, in male sGCα 1 -/-S6 than WT S6 mice, and in male sham-operated sGCα 1 -/-S6 mice than orchiectomized sGCα 1 -/-S6 mice was rescued by 20-6,15-HEDGE.
Conclusion
Gender-and strain-specific hypertension and vascular dysfunction in sGCα1 -/-S6 mice is associated with elevated CYP4a12a expression and 20-HETE levels, and is abrogated by antagonizing 20-HETE. These results corroborate our hypothesis that testosterone-induced CYP4a12a expression and a concomitant increase in 20-HETE production contribute to the hypertension associated with impaired NO-cGMP signaling and that CYP4a12a represents a candidate blood pressure modifying gene in the context of deficient NO-sGC signaling.
